Loading
A phase 1/2 trial of Zelenectide pevedotin and Pembrolizumab in bladder & urothelial cancer, triple-negative breast cancer, HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, non-small-cell lung cancer and ovarian cancer, run by BicycleTx Limited, active and no longer recruiting.
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies is a phase 1/2 interventional study registered as NCT04561362 by BicycleTx Limited, with 329 participants enrolled, started 2020-07-17 and due to reach its primary completion in 2026-03. Interventions recorded: BT8009 and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates, Bladder & urothelial cancer and the tag pipeline.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Bladder & urothelial cancer, Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), Pembrolizumab and the tag pipeline.
Shares Bicycle Therapeutics and the tag pipeline.
Shares Bicycle Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/